Maximal Recruitment Open Lung Ventilation in Acute Respiratory Distress Syndrome (PHARLAP). A Phase II, Multicenter Randomized Controlled Clinical Trial

• Published in: American journal of respiratory and critical care medicine 2019-12, Vol.200 (11), p.1363-1372
• Main Authors: Hodgson, Carol L, Cooper, D James, Arabi, Yaseen, King, Victoria, Bersten, Andrew, Bihari, Shailesh, Brickell, Kathy, Davies, Andrew, Fahey, Ciara, Fraser, John, McGuinness, Shay, Murray, Lynne, Parke, Rachael, Paul, Eldho, Tuxen, David, Vallance, Shirley, Young, Meredith, Nichol, Alistair
• Format: Article
• Language: English
• Subjects: Clinical trials; Female; Humans; Kaplan-Meier Estimate; Lung diseases; Male; Middle Aged; Positive-Pressure Respiration - methods; Positive-Pressure Respiration - mortality; Respiration, Artificial - methods; Respiration, Artificial - mortality; Respiratory Distress Syndrome, Adult - mortality; Respiratory Distress Syndrome, Adult - therapy; Respiratory therapy; Survival Analysis; Ventilators
• ISSN: 1073-449X; 1535-4970
• DOI: 10.1164/rccm.201901-0109oc

Open lung ventilation strategies have been recommended in patients with acute respiratory distress syndrome (ARDS). To determine whether a maximal lung recruitment strategy reduces ventilator-free days in patients with ARDS. A phase II, multicenter randomized controlled trial in adults with moderate to severe ARDS. Patients received maximal lung recruitment, titrated positive end expiratory pressure and further Vt limitation, or control "protective" ventilation. The primary outcome was ventilator-free days at Day 28. Secondary outcomes included mortality, barotrauma, new use of hypoxemic adjuvant therapies, and ICU and hospital stay. Enrollment halted October 2, 2017, after publication of ART (Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial), when 115 of a planned 340 patients had been randomized (57% male; mean age, 53.6 yr). At 28 days after randomization, there was no difference between the maximal lung recruitment and control ventilation strategies in ventilator-free days (median, 16 d [interquartile range (IQR), 0-21 d],  = 57, vs. 14.5 d [IQR, 0-21.5 d],  = 56;  = 0.95), mortality (24.6% [  = 14/56] vs. 26.8% [  = 15/56];  = 0.79), or the rate of barotrauma (5.2% [  = 3/57] vs. 10.7% [  = 6/56];  = 0.32). However, the intervention group showed reduced use of new hypoxemic adjuvant therapies (i.e., inhaled nitric oxide, extracorporeal membrane oxygenation, prone; median change from baseline 0 [IQR, 0-1] vs. 1 [IQR, 0-1];  = 0.004) and increased rates of new cardiac arrhythmia (  = 17 [29%] vs.  = 7 [13%];  = 0.03). Compared with control ventilation, maximal lung recruitment did not reduce the duration of ventilation-free days or mortality and was associated with increased cardiovascular adverse events but lower use of hypoxemic adjuvant therapies.Clinical trial registered with www.clinicaltrials.gov (NCT01667146).